Piet Habbel
- Neurology top 10%
- Biochemistry top 10%
-
- Metabolomics and Mass Spectrometry Studies 10
- PI3K/AKT/mTOR signaling in cancer 2
-
- Mass Spectrometry Techniques and Applications 3
- Advanced NMR Techniques and Applications 2
-
- Venous Thromboembolism Diagnosis and Management 3
-
- Advanced MRI Techniques and Applications 3
-
- Chronic Lymphocytic Leukemia Research 2
-
- Fatty Acid Research and Health 2
- Co-authors
- Lindsey A. VandergriftLeo L. ChengJohannes NowakDavid KaulIgor A. KaltashovKarsten H. WeylandtJing X. KangJan Eucker
- Partner nations
- GermanyUnited StatesChina
In The Last Decade
Piet Habbel
27 papers receiving 810 citations
Peers
Comparison fields: 5 of 105
- Biological Psychiatry 26
- Cancer Research 147
- Neurology 67
- Biochemistry 43
- Immunology 119
Countries citing papers authored by Piet Habbel
This map shows the geographic impact of Piet Habbel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Piet Habbel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Piet Habbel more than expected).
Fields of papers citing papers by Piet Habbel
This network shows the impact of papers produced by Piet Habbel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Piet Habbel. The network helps show where Piet Habbel may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Piet Habbel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2023 | 1 | |
| 3 | 2023 | 0 | |
| 4 | 2022 | 6 | |
| 5 | 2021 | 23 | |
| 6 | 2021 | 3 | |
| 7 | 2019 | 129 | |
| 8 | 2019 | 21 | |
| 9 | 2019 | 24 | |
| 10 | 2017 | 22 | |
| 11 | 2017 | 26 | |
| 12 | 2016 | 15 | |
| 13 | TKI258, a multi-tyrosine kinase inhibitor is efficacious against human infant/childhood lymphoblastic leukemia in vitro. | 2014 | 4 |
| 14 | 2014 | 36 | |
| 15 | The multi-tyrosine kinase inhibitor TKI258, alone or in combination with RAD001, is effective for treatment of human leukemia with BCR-ABL translocation in vitro. | 2014 | 5 |
| 16 | 2012 | 107 | |
| 17 | 2012 | 53 | |
| 18 | 2010 | 10 | |
| 19 | 2009 | 31 | |
| 20 | 2007 | 84 |
About Piet Habbel
Piet Habbel is a scholar working on Internal Medicine, Spectroscopy and Genetics, having authored 29 papers that have together received 817 indexed citations. Recurring topics across this work include Metabolomics and Mass Spectrometry Studies (10 papers), Mass Spectrometry Techniques and Applications (3 papers), Venous Thromboembolism Diagnosis and Management (3 papers), Advanced MRI Techniques and Applications (3 papers), Chronic Lymphocytic Leukemia Research (2 papers), PI3K/AKT/mTOR signaling in cancer (2 papers), Advanced NMR Techniques and Applications (2 papers) and Fatty Acid Research and Health (2 papers). The work is most often cited by research in Biological Psychiatry (26 citations), Cancer Research (147 citations) and Neurology (67 citations). Piet Habbel has collaborated with scholars based in Germany, United States and China. Frequent co-authors include Lindsey A. Vandergrift, Leo L. Cheng, Johannes Nowak, David Kaul, Igor A. Kaltashov, Karsten H. Weylandt, Jing X. Kang, Jan Eucker, Katja Derkow and Seija Lehnardt. Their work appears in journals such as NMR in Biomedicine, Deutsches Ärzteblatt, Scientific Reports, Prostate Cancer and Prostatic Diseases and Neurology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.